湖南訊 （來源/人民健康）哮喘是一種常見的慢性呼吸系統(tǒng)疾病，以氣道炎癥和平滑肌收縮（支氣管收縮）為主要特征，可導致呼吸困難1。

近期，阿斯利康宣布，兩項III期KALOS與LOGOS研究表明其固定三聯(lián)吸入制劑：布地格福吸入氣霧劑(320/28.8/9.6μg)達到主要終點，在患者肺功能改善方面具有顯著統(tǒng)計學意義與臨床意義。

KALOS與LOGOS為重復、隨機、雙盲試驗，旨在將布地格福吸入氣霧劑作為一項潛在的哮喘治療方法進行研究5,6。這些試驗評估了布地格福吸入氣霧劑對比ICS/LABA維持治療在未得到控制的成人和青少年哮喘患者中的有效性與安全性5,6。

阿斯利康全球執(zhí)行副總裁，生物制藥研發(fā)負責人Sharon Barr表示：“這些結(jié)果表明布地格福吸入氣霧劑有助于改善數(shù)百萬哮喘患者的生活。我們期待與監(jiān)管部門分享這些研究結(jié)果，使布地格福吸入氣霧劑能夠惠及更廣泛的患者群體。”

參考文獻

1. Global Asthma Network. The Global Asthma Report 2022. [Online]. Available at:http://globalasthmareport.org/resources/Global_Asthma_Report_2022.pdf. [Last accessed: May 2025].
2. Davis J,et al. Burden of asthma among patients adherent to ICS/LABA: A real-world study.J Asthma. 2019 Mar;56(3):332-340.
3. Buhl R,et al. One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β2-agonist in UK primary care settings.Respir Med. 2020 Feb: 162:105859.
4. Huang K,et al.Lancet. 2019 Aug 3;394(10196)407-418.
5. gov. Study to Assess PT010 in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS) [Online]. Available at:https://clinicaltrials.gov/study/NCT04609878?limit=25&term=KALOS&rank=1. [Last accessed: May 2025].
6. gov. Study to Assess PT010 in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS) [Online]. Available at:https://clinicaltrials.gov/study/NCT04609904?limit=25&term=LOGOS&rank=4. [Last accessed: Mayl 2025].